ATNM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Actinium Pharmaceuticals Inc (ATNM) is not a good buy right now for a beginner investor with a long-term focus and $50,000-$100,000 to deploy. The stock is trading at 1.22 with a weak short-term setup, no supportive proprietary buy signal, no recent news catalyst, and deteriorating financial performance. Based on the data provided, the direct conclusion is to avoid buying now.
The technical trend is weak and bearish. MACD is below zero and still negative, RSI is neutral at 50.0, and the moving averages are aligned bearishly with SMA_200 > SMA_20 > SMA_5. Price is hovering near the pivot level of 1.214, with resistance at 1.298 and 1.35, while support sits at 1.13 and 1.078. This suggests limited upside momentum and a fragile near-term structure. The stock trend model also points to only modest near-term upside and weakness over the next month.
["Options positioning is heavily call-skewed, indicating speculative bullish interest", "Price is close to the pivot level, so a short rebound is possible if support holds", "Gross margin is reported at 100%, showing the company retains strong product-level margin structure"]
["No news in the recent week, so there is no event-driven upside catalyst", "No recent AI Stock Picker or SwingMax signal", "Bearish moving average structure and negative MACD momentum", "Revenue is still 0 in the latest quarter", "Net income remains deeply negative at -5.94 million", "EPS is negative and deteriorating year over year", "Hedge funds are neutral with no significant trading trend", "Insiders are neutral with no significant trading trend", "No recent congress trading data available", "Stock trend estimate shows weakness over the next month"]
In 2025/Q4, Actinium reported revenue of 0, which is flat year over year and indicates no sales growth. Net income was -5.94 million, down 10.70% YoY, and EPS was -0.19, down 9.52% YoY. Gross margin was 100%, but that does not offset the lack of revenue and persistent losses. For a long-term beginner investor, this quarter does not show improving operating momentum.
No analyst rating or price target change data was provided, so there is no evidence of a favorable Wall Street revision trend. Based on the available information, the Wall Street view appears mixed-to-negative: there is no visible analyst upgrade momentum, no supportive news catalyst, weak technicals, and poor recent financial growth. The pros case is limited to speculative options interest and margin structure, while the cons case is dominated by losses, no revenue growth, and bearish trend signals.
